WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • WJAHR: OCTOBER ISSUE PUBLISHED

    OCTOBER 2024 Issue has been successfully launched on OCTOBER 2024.

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR October 2024 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

Best Article Awards

World Journal of Advance Healthcare Research (WJAHR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

THE IMPACT OF LONG-TERM USAGE OF PROTON PUMP INHIBITOR MEDICINES ON BLOOD LEVELS OF MAGNESIUM SALTS

*Dr. Baseem Ali Hussein and Dr. Mohammed Shakir Fashal

ABSTRACT

Introduction: Late 1980s proton pump inhibitors (PPIs) enhanced acidity-related disease treatment. They reduce stomach acid best.[1] PPIs work better than other anti-secretory drugs because they permanently inhibit the stomach H+/K+ ATPase, the final step of acid secretion. They are often recommended for GERD, peptic ulcer disease, and other stomach acid-related disorders.[2] PPIs are generally safe, however they may cause pneumonia, diarrhoea, iron and vitamin B12 deficiency, Clostridium difficile colitis, and hypomagnesemia.[3,4] Maintenance Patients with gastro-esophageal reflux illness often use PPIs. Some studies show that PPIs reduce GERD symptoms and treat esophagitis. A meta-analysis found that proton pump inhibitors relieved heartburn 11.5 percent of the time, compared to 6.4 percent for H2 receptor antagonists.[5] Esophagitis commonly returns, so acid suppression medicine is needed.[6,7] The speed of relapse after a trial off antisecretory medicines may indicate if maintenance medication is needed. Acute treatment may sustain remissions lasting more than three months, but recurring symptoms in less than three months indicate sickness best managed with continued medication.[8] Long-term drug usage (more than a year for PPIs) raises safety concerns.[9] Long-term safety concerns for proton pump inhibitors (PPIs) include stomach shrinkage, persistent hypochlorhydria and hypergastrinemia, and PPIs. Hypochlorhydria may lead to infections and malabsorption.[10] Numerous studies have connected PPI use to intestinal magnesium absorption-related hypomagnesaemia.[11] Magnesium is the body's fourth most abundant cation and second intracellular cation.[12] Magnesium is 1,000 mmols per adult (22-26gm). Healthy people have 1.5–2.0 mg/dl plasma Mg.[13] Bone contains 60% of the body's calcium, 30% of which is exchangeable and stabilises blood calcium levels. It also reinforces the skeleton. 20% is in skeletal muscle, 19% in soft tissues, and 1% in extracellular fluid.[14,15] Magnesium is needed for ATP transport and over 300 other metabolic processes. It improves heart rhythm, immunological function, muscle and neuron function, and bone density. It regulates blood pressure, sugar, protein, and energy metabolism.[16,17] The kidneys excrete Mg, the stomach absorbs it, and bone stores it.[18] Magnesium levels below 0.61 mmol/L (1.5 mg/dl) are low.[19] High-dose oral magnesium supplementation may treat hypomagnesaemia since urine magnesium excretion is low. Chronic usage of omeprazole and other proton pump inhibitors (usually over a year) may cause hypomagnesaemia (PPIs). Hypomagnesaemia disappears after PPI medication stops.[20,21] Reports indicate 38 hypomagnesaemia cases connected to PPI use.[22] The FDA issued a warning advisory acknowledging severe hypomagnesaemia connected to long-term PPI use after 15 further cases were recorded.[9] In March 2011, the FDA warned healthcare providers about hypomagnesaemia in long-term PPI users.[9] The FDA urges doctors to evaluate patients' blood magnesium levels while giving PPIs to long-term users or those on other hypomagnesemia-causing medicines (eg, digoxin or diuretics). The aim of this study was to examine the effect of the use PPIs for more than 3 months on serum magnesium level, and compare the result with serum Mg level of healthy control from adult people.

[Full Text Article] [Download Certificate]